Tag: Dr. Ebrahim Delpassand
News and Notes from the Carcinoid Cancer Foundation, July 2022
Have you wondered what it’s like to attend Grand Rounds dedicated to neuroendocrine cancer? NET expert Satya (Nanu) Das, MD, MSCI, Assistant Professor…
READ MORE
Detectnet (copper Cu 64 dotatate injection) Now Included in NCCN Guidelines® for Neuroendocrine Tumors
The newest FDA-approved PET imaging agent for neuroendocrine tumors — DetectnetTM (copper Cu 64 Dotate injection) — is now included in the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine…
READ MORE
Dr. Ebrahim Delpassand to be Featured Guest for CCF’s Luncheon with the Experts
Ebrahim S. Delpassand, MD, FACNM, Chairman and Medical Director at Excel Diagnostics & Nuclear Oncology Center in Houston, Texas and founder, Chairman of the Board, and CEO of Radiomedix in Houston, will be the featured guest for Luncheon with the…
READ MORE
15 Videos from the 3rd Theranostics World Congress
The 3rd Theranostics World Congress featured a patient education day on Saturday, March 14, made possible with support from the Carcinoid Cancer Foundation and the Caring for Carcinoid Foundation. The NorCal CarciNET Community provided funding to…
READ MORE
First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate
Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …
READ MORE
FDA Approves Amendment for PRRT Clinical Trial in Texas
BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…
READ MORE
Worldwide NET Cancer Awareness Day Update: Events from Australia to Europe to North America
Go around the globe for the second Worldwide NET Cancer Awareness Day (WNCAD) on November 10, 2011. Throughout that day, videos featuring NET events and experts will air on www.netcancerday.org as the sun travels west, from Australia to Europe to North…
READ MORE
Pancreatic Neuroendocrine Tumors: A Rare Cancer
From your next door neighbor to Steve Jobs, co-founder of Apple who just announced that he is stepping down as CEO of the company, pancreatic neuroendocrine tumors (pNETs) affect less than 1 person in 100,000 in the United States. This rare cancer is often…
READ MORE
9 Conferences for the Carcinoid and Neuroendocrine Tumor Community
If you are a carcinoid or NET cancer survivor, caregiver, family member or medical professional you can learn about what’s happening now and what’s new in carcinoid/NETs treatments, clinical trials, research, and more from specialists…
READ MORE
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE
